Baca berita tanpa iklan. Gabung Kompas.com+
December 24, 2021, 03.35 PM

KOMPAS.com - The US Food and Drug Administrator approved Merck’s Covid-19 treatment on Thursday, Dec. 23.

It will be the second at-home oral treatment available to US citizens.

It comes after it gave the go-ahead for similar treatment from Pfizer Inc. a day earlier.

Merck’s drug molnupiravir, developed with Ridgeback Biotherapeutics, inserts tiny errors into the virus’s genetic code to stop it from reducing. This has sparked concerns that the drug could spur the virus to mutate into more virulent strains.

Also readUS Approves Pfizer Pill for Covid-19 Treatment

The drug targets part of the virus known as RNA polymerase, which has not changed much in the omicron variant.

The approval provides another easy-to-use medication to battle the rising tide of infections. The molnupiravir drug is already authorized for use in the UK. It is still under review in the European Union.

Molnupiravir not as efficient as paxlovid

US federal regulators only authorized Merck’s drug for adults with early symptoms of Covid-19 who are most vulnerable to severe disease.

Pregnant women should not use molnupiravir according to the FDA.

Also read: Indonesian Health Minister to Offer Sinovac and Pfizer Vaccines for Child Jab

Men and women were also instructed to use contraception during and after the treatment.

“Molnupiravir is limited to situations where other FDA-authorized treatments for Covid-19 are inaccessible or are not clinically appropriate and will be a useful treatment option for some patients with Covid-19 at high risk of hospitalization or death,” said Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research.

The Pfizer pill works differently and doesn't carry the same risks.

Source: AFP, Reuters

Dapatkan update berita pilihan dan breaking news setiap hari dari Kompas.com. Mari bergabung di Grup Telegram "Kompas.com News Update", caranya klik link https://t.me/kompascomupdate, kemudian join. Anda harus install aplikasi Telegram terlebih dulu di ponsel.

Baca berita tanpa iklan. Gabung Kompas.com+


Baca berita tanpa iklan. Gabung Kompas.com+
Comment wisely and responsibly. Comments are entirely the responsibility of the commentator as regulated in the ITE Law
Report
Thank You! We have received your report. We will remove comments that conflict with the Community Guidelines and the ITE Law.

More Headlines

Travel & Leisure
January 24, 2023, 09.55 AM

tiket.com Offers Best Accommodation, Airfare Deals for CNY Holiday

Baca berita tanpa iklan. Gabung Kompas.com+
Baca berita tanpa iklan. Gabung Kompas.com+
Baca berita tanpa iklan. Gabung Kompas.com+
Baca berita tanpa iklan. Gabung Kompas.com+
Close Ads
Oke
Baca berita tanpa iklan. Gabung Kompas.com+